Economic Threats : Slow Growth Global Economy

CVS, a national pharmacy chain, works not only in but also with the community. The company focuses on the betterment of society. Its extensive Corporate Social Responsibility strategy, entitled Prescription for a Better World, places CVS at the center at a variety of mainstream issues. The three focal points of its CSR plan are the environment, the economic opportunities for citizens, and the health of the community (Novick O’Keefe 2014). CVS has a whole department focused on CSR, called CVS Caremark, which houses the CVS Caremark Charitable Trust. Their many projects include the end of Tobacco distribution, the betterment of school and local health care, sustainability, and charitable events.

Question 1 Several factors have been proposed as providing a rationale for mergers. Among the more prominent ones are (1) tax considerations, (2) diversification, (3)

AN example, in 2008, Hewlett Packet purchased Electronic Data Systems to enhance the services aspect of the partnering technology offerings (Yurko, 1996). Marketing networks now give companies much wider customer access including overnight services. One such merger is the Takeda Pharmaceutical Inc. Although distribution chains work great to increase the bottom line, these mergers are not well received by federal agencies like the Federal Trade Commission. The concern being monopolization which is when one company controls too much of a given industry. Another driver of mergers is a desire for a leadership change. Sometimes the owner of the high technology firms simply wants to sale out and has problems finding a successor within to take the helm. Hence, a merger holds an

The Pharmacia merger has expanded ITLT’s scope in establishing direction, strategy, and alignment of IT with the business needs. In place of 25 pharmaceutical products, we now have more than 1000 such products increasing our product portfolio, revenue, and geographical reach. The current ITLT won’t be able to address this enormous growth properly and requires significant structural and processual changes to better support Pfizer’s overall business needs.

Pfizer operates with high and sustainable gross margin, above the industry average. Though there is a reduction in revenues in 2013 compared to 2012, whereas COGS stays almost at the same level. The main reason of revenue reduction is the loss of exclusivity of branded Lipitor, Geodon and other drugs (approximately $ 3.9 billion), whereas revenue growth from other

Title of Essay: Identify three major political and economic global risks for businesses from the list of twelve discussed in week 16

Johnson & Johnson researches, develops, and manufactures products in the healthcare field in countries all around the world. They are the world’s 6th largest consumer health company, the world’s most comprehensive medical devices business, and the world’s 5th largest pharmaceuticals company. With products ranging from their Johnson’s baby wash, Band Aid brand, and self measuring glucose monitors, this company launched “Healthy Future 2015” to communicate their sustainability efforts in climate change, human rights, and advancing community wellness.

Pfizer‘s ceo Ian Reid announced that company would dissociate substantial portions of the company with the aim to focus on pharmaceuticals. Its business is divided into two divisions which are biopharmaceutical with 86% of revenues which consists of primary care, speciality care, established products, emerging markets and oncology. The diversified makes 14% of revenues which consists of consumer healthcare, animal health, nutrition among others. Some major products of biopharmaceutical (86%of total revenue) are; (sanburn, 2011)

The rising need for protection of intellectual property rights and improvement of public health lead the pharmaceutical industry to establish an agreement in 2001 with the World Trade Organization. In Sanofi’s earliest archived sustainability effort, Environmental Progress Report 2001, it states that Sanofi has taken initiatives to promote sustainable development as a reaction to the rise of wider and on going responsibilities. They have pursued these defensive efforts through promoting safety in the workplace, industrial hygiene, respecting the environment, training & investment, and many more. Sanofi is shelling out great investments for their sustainability programs. In 2001 alone, Sanofi allocated 11.2 Million Euros for a program to limit its operations’ impact on the environment. By 2008, Sanofi showed efforts of compliance with the United Nation’s Agenda 21 Blueprint for sustainability by establishing the four pillars (i.e. Patient, Ethics, Planet, and People) that serves as the foundation of their sustainability efforts . In the following year, Sanofi began its transformation to a diversified global health care company. With this, a Corporate Social Responsibility Direction was created which changed their sustainability report to an encompassing Corporate Social Responsibility (CSR) report. These efforts lead Sanofi to embed their ethical responsibilities and discretionary responsibilities into the company’s

Discontinuation of products in late stage development, its lack of promising products in its early stage pipeline and the potential geographic, and therefore revenues limitations for Pfizer through its establishment of marketing agreements for other companies' products.

Pfizer has become interested and is investing in biotechnology not only because of the patent potential, but also because the biologic compounds are significantly harder to copy by generic manufacturers (Lawler, 2007). Pfizer’s billions of dollars dedicated to research and development have been fueled by the search to be the first to patent a new blockbuster drug. The discovery of a blockbuster drug can make or break a company. In response to competition going global, Pfizer has done the same only to be forced to face problems with both counterfeiting and the protection of intellectual property (Kermani, 2006). Overall, Pfizer has been affected by global competition in numerous ways, and most of the actions Pfizer has taken as a result have made the company more profitable as a whole.

At Pfizer, were inspired by a single goal: your health. That’s why we’re dedicated to developing new, safe medicines to prevent and treat the world’s

Point A implies that a lot times a Merger is happening for the sake of it as in just because it’s a trend and it would bring the organization in the news. It may happen not for a real Business cause but for having media attention. Here the Banking institution or the Lawyer normally tries to be diplomatic and never corrects or advice their possible clients in order for their own interests being served.

The Worlds Finance Ministers and the Governors of the Central Bank gathered for their annual global finance convocation. Due to stagnation and inadequate economic growth the mood was somber. The group did not see any options for bettering the stagnation and structural changes in the global economy. The International Monetary Fund has forecasted downward and feels the global economy is entering unexplored dangerous territory. Central Banks fear they will not be able to keep up with the possible recession. Lawrence Summers (2016), writer for the Washington Post stated that “saving has become overabundant, new investment insufficient and stagnation secular rather than transient.

Pfizer Inc. is a biopharmaceutical company focused on providing access to safe, effective and affordable medicines and related health care services to the people who need them. By bridging the gap for patients in need, Pfizer believes all walks of life deserve access to quality healthcare in order to provide patients with the opportunity to live a healthy life. (Pfizer, n.d.) Pfizer accomplishes this mission by focusing attention on building healthcare capacity, expanding access to medicine, and promoting corporate citizenship. Moreover, Pfizer works alongside many research development centers and companies to provide healthcare organizations and world governments access to innovative technology and medicines to improve patient’s way of life.